(Q59616684)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22927522%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

title

Progress against solid tumors in danger: the metastatic breast cancer example (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22927522%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

main subject

metastatic breast cancer

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22927522%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

Ana Lluch

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22927522%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

12

Gabriel N Hortobagyi

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22927522%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

10

Hope S Rugo

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22927522%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

9

Edith A Perez

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22927522%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

author name string

Emiliano Calvo

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22927522%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

Antonio González-Martín

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22927522%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

Shaheenah Dawood

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22927522%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

Antonio Llombart-Cussac

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22927522%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

Leticia De Mattos-Arruda

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22927522%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

Patricia Gómez

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22927522%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

Orlando Silva

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22927522%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

language of work or name

English

0 references

publication date

27 August 2012

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22927522%20AND%20SRC:MED&resulttype=core&format=json

Journal of Clinical Oncology

12 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22927522%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

volume

30

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22927522%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

issue

28

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22927522%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

page(s)

3444-3447

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22927522%20AND%20SRC:MED&resulttype=core&format=json

Safety of bevacizumab in patients with advanced cancer: a meta-analysis of randomized controlled trials.

12 February 2020

cites work

1 reference

12 December 2020

Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer

1 reference

12 December 2020

Risk of Venous Thromboembolism With Bevacizumab in Cancer Patients

1 reference

12 December 2020

Congestive heart failure risk in patients with breast cancer treated with bevacizumab.

1 reference

12 December 2020

The use of bevacizumab among women with metastatic breast cancer: a survey on clinical practice and the ongoing controversy

1 reference

12 December 2020

Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study.

1 reference

12 December 2020

Overall survival as the outcome for randomized clinical trials with effective subsequent therapies

1 reference

12 December 2020

Disease course patterns after discontinuation of bevacizumab: pooled analysis of randomized phase III trials

1 reference

12 December 2020

Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis

1 reference

12 December 2020

Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer

1 reference

12 December 2020

Is breast cancer survival improving?

1 reference

12 December 2020

Systematic review of aromatase inhibitors in the first-line treatment for hormone sensitive advanced or metastatic breast cancer

1 reference

12 December 2020

Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab

1 reference

12 December 2020

Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer

1 reference

12 December 2020

Cancer statistics, 2012

1 reference

12 December 2020

Adverse events risk associated with bevacizumab addition to breast cancer chemotherapy: a meta-analysis

1 reference

12 December 2020

Everolimus for advanced pancreatic neuroendocrine tumors.

1 reference

12 December 2020

Gemcitabine plus Paclitaxel versus Paclitaxel monotherapy in patients with metastatic breast cancer and prior anthracycline treatment

1 reference

12 December 2020

Survival-adjusted health-related quality of life (HRQL) among patients with metastatic breast cancer receiving paclitaxel plus bevacizumab versus paclitaxel alone: results from Eastern Cooperative Oncology Group Study 2100 (E2100).

1 reference

12 December 2020

Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results from the randomized phase III TAnDEM

1 reference

12 December 2020

1 reference

12 December 2020

Independent adjudication of symptomatic heart failure with the use of doxorubicin and cyclophosphamide followed by trastuzumab adjuvant therapy: a combined review of cardiac data from the National Surgical Adjuvant breast and Bowel Project B-31 and

1 reference

12 December 2020

Psychological problems of cancer patients: a cancer distress screening with a cancer-specific questionnaire

1 reference

12 December 2020

Risk of gastrointestinal perforation in patients with cancer treated with bevacizumab: a meta-analysis

1 reference

12 December 2020

Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a german breast group 26/breast international group 03-05 study.

1 reference

12 December 2020

Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group

1 reference

12 December 2020

Detecting an overall survival benefit that is derived from progression-free survival

1 reference

12 December 2020

Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results

1 reference

12 December 2020

Independent review of E2100: a phase III trial of bevacizumab plus paclitaxel versus paclitaxel in women with metastatic breast cancer

1 reference

12 December 2020

Lapatinib plus capecitabine for HER2-positive advanced breast cancer

1 reference

12 December 2020

RIBBON-2: a randomized, double-blind, placebo-controlled, phase III trial evaluating the efficacy and safety of bevacizumab in combination with chemotherapy for second-line treatment of human epidermal growth factor receptor 2-negative metastatic br

1 reference

12 December 2020

RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer

1 reference

12 December 2020

Identifiers

DOI

10.1200/JCO.2012.41.9580

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22927522%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22927522%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

1 reference